FTI-277 TFA 是一种法尼基转移酶 (FTase) 抑制剂,可抑制 Ras 法尼基化,阻断下游 ERK1/2、mTOR 的磷酸化,并减少膜结合的活性 N-ras 蛋白,同时可激活 caspase 3、上调 Bim 表达、诱导细胞凋亡 (apoptosis)、抑制调节性 T 细胞扩增、增强巨噬细胞吞噬作用并改善细菌清除能力,还可激活 PI3K/Akt 信号通路、抑制成骨细胞分化并降低神经母细胞瘤细胞增殖能力,可用于头颈部鳞状细胞癌、神经母细胞瘤、脓毒症和血管钙化的相关研究。
产品编号: MS-C35191 CAS No.: 1217447-06-7 分子式: C24H30F3N3O5S2 分子量: 561.64
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

FTI-277 TFA 是一种法尼基转移酶 (FTase) 抑制剂,可抑制 Ras 法尼基化,阻断下游 ERK1/2、mTOR 的磷酸化,并减少膜结合的活性 N-ras 蛋白,同时可激活 caspase 3、上调 Bim 表达、诱导细胞凋亡 (apoptosis)、抑制调节性 T 细胞扩增、增强巨噬细胞吞噬作用并改善细菌清除能力,还可激活 PI3K/Akt 信号通路、抑制成骨细胞分化并降低神经母细胞瘤细胞增殖能力,可用于头颈部鳞状细胞癌、神经母细胞瘤、脓毒症和血管钙化的相关研究。

生物实验数据

生物活性 FTI-277 TFA is a farnesyltransferase (FTase) inhibitor that inhibits Ras farnesylation, blocks the phosphorylation of downstream ERK1/2 and mTOR, and reduces membrane-bound active N-ras protein; it also activates caspase 3, upregulates Bim expression, induces apoptosis, suppresses regulatory T cell expansion, enhances macrophage phagocytosis, and improves bacterial clearance, while activating the PI3K/Akt signaling pathway, inhibiting osteoblast differentiation, and reducing neuroblastoma cell proliferation, and it can be used for research related to head and neck squamous cell carcinoma, neuroblastoma, sepsis, and vascular calcification.
体外研究
(In Vitro)

FTI-277 (1-40 μM; 24-72 h) TFA 以浓度依赖的方式降低 HEp-2 头颈部鳞状细胞癌细胞的活力,在最高测试浓度 (40 μM) 处理 72 h 后,细胞活力下降 58.5%。
FTI-277 (0.5-10 μM; 24-72 h) TFA 以浓度依赖的方式降低 HSC-3 头颈部鳞状细胞癌细胞的活力,在最高测试浓度 (10 μM) 处理 72 h 后,细胞活力下降 77.0%,且对 HSC-3 细胞的效力高于 HEp-2 细胞。
FTI-277 (40 μM; 36 h) TFA 可显著提高 HEp-2 头颈部鳞状细胞癌细胞中的 caspase-3 活性。
FTI-277 (5 μM; 36 h) TFA 可显著提高 HSC-3 头颈部鳞状细胞癌细胞中的 caspase-3 活性,其效力高于对 HEp-2 细胞的作用。
FTI-277 (40 μM; 36 h) TFA 可显著提高头颈部鳞状细胞癌 HEp-2 细胞中膜联蛋白 V 阳性细胞的比例,表明其可诱导细胞凋亡。
FTI-277 (5 μM; 36 h) TFA 可显著提高 HSC-3 头颈部鳞状细胞癌细胞中膜联蛋白 V 阳性细胞的比例,表明其可诱导细胞凋亡,且对该细胞的作用效力强于对 HEp-2 细胞的作用。
FTI-277 (40 μM; 48 h) TFA 可抑制 Ras 的膜定位,降低 ERK1/2 和 mTOR 的磷酸化水平,并上调 HEp-2 头颈部鳞状细胞癌细胞中 Bim 蛋白的表达。
FTI-277 (5 μM; 48 h) TFA 可抑制 Ras 的膜定位,降低 ERK1/2 和 mTOR 的磷酸化水平,并上调 HSC-3 头颈部鳞状细胞癌细胞中 Bim 蛋白的表达,其效力强于对 HEp-2 细胞的作用。
FTI-277 (5 μM; 72 h) TFA 可显著降低转染 NW7 v-H-Ras 的 NIH3T3 细胞存活率,但对转染 NV20 空载体的 NIH3T3 细胞无显著作用,表明其对 Ras 过表达细胞具有选择性活性。
FTI-277 (1-20 μM; 8-10 days) TFA 可抑制原代牛血管平滑肌细胞的成骨分化及 βGP 诱导的矿化,在浓度 ≥10 μM 时可观察到显著效应,且即使在 βGP 处理启动后 6 天加入该试剂仍有效。
FTI-277 (10 μM; 77 h) TFA 在随后进行血清饥饿和短期血清刺激时,可增强原代牛血管平滑肌细胞中 Akt 的磷酸化水平。
FTI-277 (10-20 μM; 9-10 days) TFA 在 βGP 诱导的原代牛血管平滑肌细胞矿化过程中维持 Akt 的磷酸化水平,且该 Akt 激活作用是 FTI-277 发挥矿化抑制效应所必需的。
FTI-277 (10 μM) TFA 可抑制磷酸盐诱导的人冠状动脉血管平滑肌细胞凋亡,且该效应依赖于 Akt 激活。
FTI-277 (10 μM; 96 h) TFA 可使 IMR-5 神经母细胞瘤细胞中法尼基化 N-Ras 蛋白水平降低约 50%。
FTI-277 (10 μM; 96 h) TFA 可使 IMR-5 神经母细胞瘤细胞中的基础 MAP-激酶活性降低约 47%,并将 BDNF 诱导的 MAP-激酶激活抑制至对照组水平的 35%。
FTI-277 (10 μM; 96 h) TFA 可将 IMR-5 神经母细胞瘤细胞中基础 N-myc 的表达水平降至对照组的 70%,并将 BDNF 诱导的 N-myc 表达水平抑制至对照组刺激水平的 53%。
FTI-277 (10 μM; 96 h) TFA 可显著降低 IMR-5 神经母细胞瘤细胞在完全培养基、无血清培养基及 BDNF 补充培养基中的增殖能力,并完全消除 BDNF 诱导的该细胞增殖。

Cell Viability Assay

Cell Line: HEp-2 head and neck squamous cell carcinoma cells
Concentration: 1 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Time: 24 h, 48 h, 72 h
Result: Decreased HEp-2 cell viability in a concentration-dependent manner.
Reduced cell viability to 97.9% with 1 μM, 98.9% with 5 μM, 89.1% with 10 μM, 78.3% with 20 μM, and 41.5% with 40 μM after 72 h treatment.
Induced statistically significant viability reductions with 20 μM and 40 μM at 48 h, and with 10 μM, 20 μM, and 40 μM at 72 h relative to controls.

Cell Viability Assay

Cell Line: HSC-3 head and neck squamous cell carcinoma cells
Concentration: 1 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Time: 24 h, 48 h, 72 h
Result: Decreased HSC-3 cell viability in a concentration-dependent manner, with greater potency than in HEp-2 cells.
Reduced cell viability to 89.7% with 0.5 μM, 69.1% with 1 μM, 52.9% with 2.5 μM, 33.4% with 5 μM, and 23.0% with 10 μM after 72 h treatment.
Induced statistically significant viability reductions with all tested concentrations at 24, 48, and 72 h relative to controls.

Apoptosis Analysis

Cell Line: HEp-2 head and neck squamous cell carcinoma cells
Concentration: 40 μM
Incubation Time: 36 h
Result: Increased the percentage of annexin V-positive HEp-2 cells to approximately 42%, relative to control cells with approximately 7% annexin V-positive cells.
Induced statistically significant elevation of annexin V-positive cells, indicating apoptosis induction.

Apoptosis Analysis

Cell Line: HSC-3 head and neck squamous cell carcinoma cells
Concentration: 5 μM
Incubation Time: 36 h
Result: Increased the percentage of annexin V-positive HSC-3 cells to approximately 47%, relative to control cells with approximately 9% annexin V-positive cells.
Induced statistically significant elevation of annexin V-positive cells, indicating apoptosis induction with greater potency than against HEp-2 cells.

Western Blot Analysis

Cell Line: HEp-2 head and neck squamous cell carcinoma cells
Concentration: 40 μM
Incubation Time: 48 h
Result: Inhibited Ras membrane localization and increased Ras cytoplasmic localization in HEp-2 cells.
Decreased the expression of phosphorylated ERK1/2 and phosphorylated mTOR.
Increased the expression of Bim protein, relative to control cells.

Western Blot Analysis

Cell Line: HSC-3 head and neck squamous cell carcinoma cells
Concentration: 5 μM
Incubation Time: 48 h
Result: Inhibited Ras membrane localization and increased Ras cytoplasmic localization in HSC-3 cells.
Decreased the expression of phosphorylated ERK1/2 and phosphorylated mTOR.
Increased the expression of Bim protein, relative to control cells.
Demonstrated greater potency than against HEp-2 cells.

Cell Viability Assay

Cell Line: NV20 empty vector-transfected NIH3T3 cells, NW7 v-H-Ras-transfected NIH3T3 cells
Concentration: 5 μM
Incubation Time: 72 h
Result: Had no significant effect on the viability of NV20 empty vector-transfected NIH3T3 cells.
Significantly reduced the viability of NW7 v-H-Ras-transfected NIH3T3 cells to approximately 35%, relative to untreated NW7 cells.
Exhibited selective activity against Ras-overexpressing cells.

Western Blot Analysis

Cell Line: IMR-5 neuroblastoma cells
Concentration: 10 μM
Incubation Time: 96 h
Result: Reduced farnesylated N-Ras protein levels by 47%.\nReduced basal MAP-kinase activity by 47% compared to untreated controls.
Blunted BDNF-induced MAP-kinase activation to 35% of control levels.

RT-PCR

Cell Line: IMR-5 neuroblastoma cells
Concentration: 10 μM
Incubation Time: 96 h
Result: Reduced basal N-myc expression to 70% of untreated control levels.
Blunted BDNF-induced N-myc expression to 53% of control-stimulated levels.

Cell Proliferation Assay

Cell Line: IMR-5 neuroblastoma cells
Concentration: 10 μM
Incubation Time: 96 h
Result: Decreased cell numbers by 10% in complete medium over 48 hours, compared to an ~80% increase in untreated controls.
Resulted in significantly lower cell numbers than controls in serum-free medium.
Abolished BDNF-induced 22% proliferation increase seen in control cells in serum-free medium.
Reduced cell proliferation significantly across all three media conditions.
体内研究
(In Vivo)

FTI-277 (25 mg/kg;腹腔注射;单次给药) TFA 于 CLP 术后 2 小时给药可将脓毒症小鼠的死亡率降至 67% 的存活率,同时可改善细菌清除能力、逆转免疫功能障碍并抑制脓毒症诱导的蛋白法尼基化。

Animal Model: C57BL/6 (male, 7 weeks of age, sepsis induced by cecal ligation and puncture)
Dosage: 25 mg/kg
Administration: i.p.; single dose
Result: Increased survival rate of septic mice to 67% (10/15 survived to 7 days) compared to 7% (1/15) in vehicle-treated group.
Significantly reduced bacterial colony-forming units in blood and peritoneal cavity at 16 hours post-CLP.
Almost completely blocked sepsis-induced increase in serum HMGB1 concentration at 16 hours post-CLP.
Reduced percentage of TUNEL-positive apoptotic cells in spleen from ~7% to ~2% and in thymus from ~9% to ~1% at 16 hours post-CLP.
Reversed sepsis-induced increase in splenic farnesylated protein levels and farnesyltransferase activity to sham-equivalent levels at 16 hours post-CLP.
Partially reversed sepsis-induced increase in splenic CD4+Foxp3+ regulatory T cells from ~22% to ~15% of total CD4+ cells without altering total CD4+ splenocyte counts.
Restored IFN-γ secretion from ~30 pg/mL to ~100 pg/mL and splenocyte proliferative response to sham-equivalent levels, and reversed sepsis-induced decrease in IFN-γ to IL-4 ratio.
Reduced sepsis-induced increases in PD-L1 and PD-1 expression on splenic CD4+ T cells and macrophages.
Increased phagocytotic activity of peritoneal F4/80+ macrophages, with percentage of fluorescent microsphere-positive cells rising from ~45% to ~65% and mean fluorescence intensity per cell rising from ~220 to ~300.

化学信息

分子量 561.64
分子式 C24H30F3N3O5S2
CAS No. 1217447-06-7

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础